MIV-701 Preclinical efficacy data presented

MIV-701 Preclinical efficacy data presented

Medivir has presented efficacy data for MIV-701 in a preclinical osteoporosis
model at the ongoing conference of the American Society for Bone and Mineral
Research in Hawaii.

The results demonstrate that administration of MIV-701 in this preclinical
disease model significantly reduces osteoclast cell activity via inhibition of
the enzyme cathepsin K. An increase in osteoclast activity leads to bone
degradation and consequently osteoporosis. The activity of MIV-701 is reversible
(i.e. ceases when administration no longer is continued), which is a big
therapeutic advantage over other treatment regimes such as the bisphosphonates
which are the conventional form of treatment today.

MIV-701 is currently in phase I clinical trials (where the safety, tolerability
and pharmacokinetics of the drug compound is studied in healthy volunteers). The
first studies (phase Ia) are now completed and the phase Ib is underway. This
study includes an arm with post-menopausal women (a population often afflicted
with osteoporosis) in which the efficacy of MIV-701 on a biomarker for
osteoporosis will be studied. The phase I clinical trials are expected to be
completed and ready for evaluation before the end of the year, and the results
will be communicated thereafter.


For additional information, please contact
Rein Piir, CFO & VP, Investor Relations, Medivir AB, +46 8 5468 3123 
or +46 ¬708 537 292

For more information on Medivir, please see the company website: www.medivir.se